


MAY 18-21, 2024 | WASHINGTON, D.C. EXHIBIT DATES: MAY 19-21, 2024


Stool-derived eukaryotic RNA assay approximates disease activity index and predict therapeutic response in patients with Crohn's disease on advanced therapies

Erica K. Barnell^{1,2}, Ryan Ghannam², Ali Osman^{3,4}, Richard Roberts², Patrick Donohough¹, Spencer King², Jack Land², Clayton Grass², Matthew A. Ciorba³, Parakkal Deepak³ ¹Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

- ²Geneoscopy, Saint Louis MO, USA
- ³Inflammatory Bowel Diseases Center, Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA;
- ⁴Division of Hospital Medicine, Washington University School of Medicine, St. Louis, MO, USA

RNA calprotectin levels were more specific than protein calprotectin levels when correlating with disease and disease severity.







Classifiers were 81% accurate in parsing subjects with active disease from those in remission and 92% accurate in parsing subjects with moderate disease from those with mild disease.

IBD OUTPUT REPORT

MEASURING RNA CALPROTECTIN





ASSESSING DISEASE ACTIVITY



IDENTIFYING DYSPLASIA



ABNORMAL

PREDICTING THERAPEUTIC RESPONSE



ENTYVIO (vedolizumab)

ITGA4 / ITGB7

SENSITIVE



STELARA (ustekinumab)

IL12 / IL23


RESISTANT




REMICADE (infliximab)

TNF / TNFR


RESISTANT



Relative cell abundance and expression of transcripts associated with the therapeutic target permit enrichment of responders.




SAMPLE COLLECTION LOGISTICS





Test






Receives Kit










Processes Kit





Geneoscopy Results Report

*Geneoscopy can also assess banked frozen stool